Top 300 Pharmacy Drug Cards


Class: Proton Pump Inhibitor

Dosage Forms. Capsule, Delayed Release: 20 mg, 40 mg; Granules: 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg

Common FDA Label Indication, Dosing, and Titration.

1. Helicobacter pylori GI infection: 40 mg po daily × 10-14 d in combination with amoxicillin 1000 mg and clarithromycin 500 mg po bid

2. Erosive esophagitis, gastroesophageal reflux disease treatment: Children 1-11 y and <20 kg, 10 mg po daily × 8 wk; Children ≥20 kg, 10-20 mg po daily × 8 wk; Adults, 20-40 mg po daily × 4-8 wk

3. Erosive esophagitis, heartburn: Children 1-11 y old, 10 mg po daily × 8 wk; Children 12 y and older and Adults, 20-40 mg po daily × up to 8 wk

4. Prevention of NSAID-induced gastropathy: 20-40 mg po daily × up to 6 mo

5. Zollinger-Ellison syndrome: 40 mg po bid up to 240 mg/d


Off-Label Uses. None

MOA. Esomeprazole is a proton pump inhibitor (PPI) that, when protonated in the secretory canaliculi of the parietal cells, covalently bind to H+/K+-ATPase (proton pump), which is the final pathway for acid secretion. Esomeprazole produces a profound and prolonged antisecretory effect and inhibit basal, nocturnal, pentagastrin-stimulated, and food-stimulated gastric acid secretion.

Drug Characteristics: Esomeprazole


Medication Safety Issues: Esomeprazole


Drug Interactions: Esomeprazole


Adverse Reactions: Esomeprazole


Efficacy Monitoring Parameters. Resolution of GI discomfort, resolution of ulcers shown on endoscopy; for treatment of Helicobacter pylori, negative urea breath test.

Toxicity Monitoring Parameters. Severe headache or blistering skin rash.

Key Patient Counseling Points. Should be taken 1 h before meals.

Clinical Pearls. Multiple Helicobacter pylori regimens contain different combinations of PPIs and antibiotics; complete full regimen if prescribed for Helicobacter pylori treatment. Many PPI and H2 antagonists available OTC; warn patients not to take multiple products concurrently. Also available in injectable formulation. Increased risk of fractures, use lowest effective dose in patients at risk for osteoporosis.

If you find an error or have any questions, please email us at Thank you!